Asia Beat: All aboard the China generics express
This article was originally published in Scrip
Extraordinary times call for extraordinary measures. In a trend that frankly would have been scarcely creditable just a few years ago, research-based multinationals are buying or allying with generics firms in China.
You may also be interested in...
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.